Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
Background Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of uncertainty about the benefit for preventing major or fatal thromboembolic events, and the risk of bleeding. Methods and Results We assessed the be...
Saved in:
Main Authors: | Gary E. Raskob, Alex C. Spyropoulos, Theodore E. Spiro, Wentao Lu, Zhong Yuan, Bennett Levitan, Eunyoung Suh, Elliot S. Barnathan |
---|---|
Format: | article |
Language: | EN |
Published: |
Wiley
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/b3ae24eeae734c9d9ca797881cf8076b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EVALUATION OF EFFICIENCY AND SAFETY OF THROMBOPROPHYLAXIS AFTER ORTHOPEDIC OPERATIONS
by: A. V. Vybivantseva, et al.
Published: (2012) -
Equivalent VTE rates after total joint arthroplasty using thromboprophylaxis with aspirin versus potent anticoagulants: retrospective analysis of 4562 cases across a diverse healthcare system
by: Chelsea Matzko, et al.
Published: (2021) -
Rivaroxaban in acute venous thromboembolism: UK prescribing experience
by: Victoria Speed, et al.
Published: (2021) -
Thromboprophylaxis Measures to Prevent Venous Thromboembolism in Hospitalized Patients
by: Dilceu Silveira Tolentino Júnior, et al.
Published: (2020) -
Rivaroxaban triggered multifocal intratumoral hemorrhage of the cabozantinib-treated diffuse brain metastases: A case report and review of literature
by: Chen Luyue, et al.
Published: (2021)